Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Teams With OSU to Develop SELDI-Based Dx for Rare Blood Disorder

NEW YORK (GenomeWeb News) — Ciphergen Biosystems today said it has struck an agreement with the Ohio State University Research Foundation to develop and validate a test to help detect the blood disease thrombotic thrombocytopenic purpura.
 
The partnership aims to discover a clinical diagnostic test that can “rapidly detect” deficiencies in the enzyme activity associated with the disorder, commonly called TTP, which affects blood coagulation.
 
Under the agreement, Ciphergen will work with OSURF to develop an assay to measure enzyme and antibody inhibition activity that they will test together in a series of multi-center studies.
 
Ciphergen CSO Eric Fung said it will use a SELDI-based test for “accurately measuring the product of enzymatic chain reaction that underlies the disease” in order to help doctors manage the disease and the effects of treatment.
 
Financial terms of the agreement were not released.

The Scan

New Study Highlights Role of Genetics in ADHD

Researchers report in Nature Genetics on differences in genetic architecture between ADHD affecting children versus ADHD that persists into adulthood or is diagnosed in adults.

Study Highlights Pitfall of Large Gene Panels in Clinical Genomic Analysis

An analysis in Genetics in Medicine finds that as gene panels get larger, there is an increased chance of uncovering benign candidate variants.

Single-Cell Atlas of Drosophila Embryogenesis

A new paper in Science presents a single-cell atlas of fruit fly embryonic development over time.

Phage Cocktail Holds Promise for IBD

Researchers uncovered a combination phage therapy that targets Klebsiella pneumonia strains among individuals experiencing inflammatory bowel disease flare ups, as they report in Cell.